(Q56449002)

English

Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE):

article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

lopinavir/ritonavir

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

André Cabié

18

0 references

Hernando Knobel

object named as

Hernando Knobel

17

0 references

Joaquín Portilla

object named as

Joaquín Portilla

11

0 references

Federico Pulido

object named as

Federico Pulido

15

0 references

Vicente Estrada

object named as

Vicente Estrada

8

0 references

Pierre-Marie Girard

2

object named as

Pierre-Marie Girard

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

José R Arribas

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Roland Landman

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Judit Pich

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Josep Mallolas

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

María Martínez-Rebollar

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Francisco X Zamora

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Manuel Crespo

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Daniel Podzamczer

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Fernando Dronda

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

José A Iribarren

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Pere Domingo

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Marta Montero

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Laurence Weiss

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

José M Gatell

20

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Vicente Estrada

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Joaquín Portilla

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Federico Pulido

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Hernando Knobel

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

André Cabié

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

OLE/RIS-EST13 Study Group

21

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

language of work or name

0 references

publication date

7 June 2015

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Lancet Infectious Diseases

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

785-792

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA Panel.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900096-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the ran

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900096-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Ritonavir-boosted darunavir combined with raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900096-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazana

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900096-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900096-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority tri

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900096-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Interval estimation for the difference between independent proportions: comparison of eleven methods

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900096-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900096-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900096-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900096-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of tenofovir disoproxil fumarate on whole-body insulin sensitivity, lipids and adipokines in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900096-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Equivalent steady-state pharmacokinetics of lamivudine in plasma and lamivudine triphosphate within cells following administration of lamivudine at 300 milligrams once daily and 150 milligrams twice daily

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900096-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1473-3099(15)00096-1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26062880%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56449002&oldid=1985472038"